272 related articles for article (PubMed ID: 32533868)
1. Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries.
Bloch EM; Goel R; Wendel S; Burnouf T; Al-Riyami AZ; Ang AL; DeAngelis V; Dumont LJ; Land K; Lee CK; Oreh A; Patidar G; Spitalnik SL; Vermeulen M; Hindawi S; Van den Berg K; Tiberghien P; Vrielink H; Young P; Devine D; So-Osman C
Vox Sang; 2021 Jan; 116(1):18-35. PubMed ID: 32533868
[TBL] [Abstract][Full Text] [Related]
2. Promoting access to COVID-19 convalescent plasma in low- and middle-income countries.
Bloch EM; Goel R; Montemayor C; Cohn C; Tobian AAR
Transfus Apher Sci; 2021 Feb; 60(1):102957. PubMed ID: 32972861
[TBL] [Abstract][Full Text] [Related]
3. Blood Banking Capacity in Low-and Middle-Income Countries: Covid-19 Convalescent Plasma in Context.
Bloch EM
Curr Top Microbiol Immunol; 2024 May; ():. PubMed ID: 38772969
[TBL] [Abstract][Full Text] [Related]
4. Screening donors for COVID-19 convalescent plasma.
Wang HE; Ostrosky-Zeichner L; Katz J; Wanger A; Bai Y; Sridhar S; Patel B
Transfusion; 2021 Apr; 61(4):1047-1052. PubMed ID: 33368395
[TBL] [Abstract][Full Text] [Related]
5. Hospital-Based Donor Recruitment and Predonation Serologic Testing for COVID-19 Convalescent Plasma.
Balcerek J; Trejo E; Levine K; Couey P; Kornberg ZV; Rogine C; Young C; Li PJ; Shy BR; Taylor JE; Bakhtary S; Friedlander T; Lynch KL; Bern C; Esensten JH
Am J Clin Pathol; 2021 Mar; 155(4):515-521. PubMed ID: 33399201
[TBL] [Abstract][Full Text] [Related]
6. Clinical use of Convalescent Plasma in the COVID-19 pandemic: a transfusion-focussed gap analysis with recommendations for future research priorities.
Al-Riyami AZ; Schäfer R; van den Berg K; Bloch EM; Estcourt LJ; Goel R; Hindawi S; Josephson CD; Land K; McQuilten ZK; Spitalnik SL; Wood EM; Devine DV; So-Osman C
Vox Sang; 2021 Jan; 116(1):88-98. PubMed ID: 32542847
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 antibody changes in patients receiving COVID-19 convalescent plasma from normal and vaccinated donors.
Leon J; Merrill AE; Rogers K; Kurt J; Dempewolf S; Ehlers A; Jackson JB; Knudson CM
Transfus Apher Sci; 2022 Apr; 61(2):103326. PubMed ID: 34862140
[TBL] [Abstract][Full Text] [Related]
8. Deterrents in recruitment of COVID-19 convalescent plasma donors: Experience from a hospital-based blood centre in India.
Dhiman Y; Coshic P; Pandey HC; Khatiwada B; Singh J; Mehta V; Gupta S
Transfus Med; 2021 Jun; 31(3):149-154. PubMed ID: 33749020
[TBL] [Abstract][Full Text] [Related]
9. Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): An organizational model for future emergencies.
De Silvestro G; Gandini G; Fiorin F; Marson P; Barbone E; Frigato A; Gessoni G; Veronesi A; Pacenti M; Castelli M; Rinaldi M; Rizzi M; Stefani F; Roveroni G
Transfus Apher Sci; 2021 Aug; 60(4):103154. PubMed ID: 33994107
[TBL] [Abstract][Full Text] [Related]
10. International Society of Blood Transfusion survey of experiences of blood banks and transfusion services during the COVID-19 pandemic.
Al-Riyami AZ; Burnouf T; Wood EM; Devine DV; Oreh A; Apelseth TO; Goel R; Bloch EM; van Den Berg K; Getshen M; Louw V; Ang AL; Lee CK; Rahimi-Levene N; Stramer SL; Vassallo R; Schulze TJ; Patidar GK; Pandey HC; Dubey R; Badawi M; Hindawi S; Meshi A; Matsushita T; Sorrentino E; Grubovic Rastvorceva RM; Bazin R; Vermeulen M; Nahirniak S; Tsang HC; Vrielink H; Triyono T; Addas-Carvalho M; Hećimović A; Torres OW; Mutindu SM; Bengtsson J; Dominguez D; Sayedahmed A; Hanisa Musa R; Gautam B; Herczenik E; So-Osman C;
Vox Sang; 2022 Jun; 117(6):822-830. PubMed ID: 35262978
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 convalescent plasma donor characteristics, product disposition, and comparison with standard apheresis donors.
Lasky B; Goodhue Meyer E; Steele WR; Crowder LA; Young PP
Transfusion; 2021 May; 61(5):1471-1478. PubMed ID: 33458811
[TBL] [Abstract][Full Text] [Related]
12. Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019.
Bloch EM; Focosi D; Shoham S; Senefeld J; Tobian AAR; Baden LR; Tiberghien P; Sullivan DJ; Cohn C; Dioverti V; Henderson JP; So-Osman C; Juskewitch JE; Razonable RR; Franchini M; Goel R; Grossman BJ; Casadevall A; Joyner MJ; Avery RK; Pirofski LA; Gebo KA
Clin Infect Dis; 2023 Jun; 76(11):2018-2024. PubMed ID: 36740590
[TBL] [Abstract][Full Text] [Related]
13. Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA Thresholds.
Larkey NE; Ewaisha R; Lasho MA; Roforth MM; Granger D; Jerde CR; Wu L; Gorsh A; Klassen SA; Senefeld JW; Joyner MJ; Baumann NA; Theel ES; Mills JR
Microbiol Spectr; 2022 Aug; 10(4):e0115422. PubMed ID: 35862939
[TBL] [Abstract][Full Text] [Related]
14. Blood group O convalescent plasma donations have significantly lower levels of SARS-CoV-2 IgG antibodies compared to blood group A donations.
Hayes C; Rubenstein W; Gibb D; Klapper E; Tanaka J; Pepkowitz S
Transfusion; 2021 Aug; 61(8):2245-2249. PubMed ID: 34036595
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China.
Li L; Yang R; Wang J; Lv Q; Ren M; Zhao L; Chen H; Xu H; Xie S; Xie J; Lin H; Li W; Fang P; Gong L; Wang L; Wu Y; Liu Z
Transfusion; 2020 Aug; 60(8):1773-1777. PubMed ID: 32491199
[TBL] [Abstract][Full Text] [Related]
16. How do I implement an outpatient program for the administration of convalescent plasma for COVID-19?
Bloch EM; Tobian AAR; Shoham S; Hanley DF; Gniadek TJ; Cachay ER; Meisenberg BR; Kafka K; Marshall C; Heath SL; Shenoy A; Paxton JH; Levine A; Forthal D; Fukuta Y; Huaman MA; Ziman A; Adamski J; Gerber J; Cruser D; Kassaye SG; Mosnaim GS; Patel B; Metcalf RA; Anjan S; Reisler RB; Yarava A; Lane K; McBee N; Gawad A; Raval JS; Zand M; Abinante M; Broderick PB; Casadevall A; Sullivan D; Gebo KA
Transfusion; 2022 May; 62(5):933-941. PubMed ID: 35352362
[TBL] [Abstract][Full Text] [Related]
17. How we secured a COVID-19 convalescent plasma procurement scheme in Japan.
Terada M; Kutsuna S; Togano T; Saito S; Kinoshita N; Shimanishi Y; Suzuki T; Miyazato Y; Inada M; Nakamoto T; Nomoto H; Ide S; Sato M; Maeda K; Matsunaga A; Satake M; Matsubayashi K; Tsuno H; Kojima M; Kuramistu M; Tezuka K; Ikebe E; Okuma K; Hamaguchi I; Shiratori K; Sato M; Kawakami Y; Inaba K; Igarashi S; Yamauchi R; Matsumura M; Ishimaru K; Zhang B; Kuge C; Ishihara M; Gouda M; Tanaka K; Ishizaka Y; Ohmagari N
Transfusion; 2021 Jul; 61(7):1998-2007. PubMed ID: 34096059
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 neutralizing capacity among blood donors without prior COVID-19 symptomatic history vs. blood donors with prior COVID-19 symptomatic history: A comparative study.
Ravula U; Chunchu SR; Mooli S; Naik R; Sarangapati PRR
Transfus Clin Biol; 2022 May; 29(2):107-111. PubMed ID: 35167958
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 convalescent plasma cohort study: Evaluation of the association between both donor and recipient neutralizing antibody titers and patient outcomes.
Yokoyama APH; Wendel S; Bonet-Bub C; Fachini RM; Dametto APF; Blumm F; Dutra VF; Candelaria GTP; Sakashita AM; Machado RRG; Fontão-Wendel R; Hamerschlak N; Achkar R; Assunção MSC; Scuracchio P; Nudelman V; Pastore L; Pinho JRR; Ben MD; Filho RK; Marra AR; Amano MT; Kallás EG; Helito AS; de Carvalho CRR; Araujo DB; Durigon EL; Camargo AA; Rizzo LV; Reis LFL; Kutner JM
Transfusion; 2021 Aug; 61(8):2295-2306. PubMed ID: 34173248
[TBL] [Abstract][Full Text] [Related]
20. Factors driving availability of COVID-19 convalescent plasma: Insights from a demand, production, and supply model.
Russell WA; Grebe E; Custer B
Transfusion; 2021 May; 61(5):1370-1376. PubMed ID: 33590906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
